1
|
Lu Y, Liu X, Zhao T, Ding C, Ding Q, Wang N, Ma S, Ma L, Liu W. Synthesis of Taxifolin-Loaded Polydopamine for Chemo-Photothermal-Synergistic Therapy of Ovarian Cancer. Molecules 2024; 29:1042. [PMID: 38474556 DOI: 10.3390/molecules29051042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2024] [Revised: 02/11/2024] [Accepted: 02/26/2024] [Indexed: 03/14/2024] Open
Abstract
Chemotherapy is a well-established method for treating cancer, but it has limited effectiveness due to its high dosage and harmful side effects. To address this issue, researchers have explored the use of photothermal agent nanoparticles as carriers for precise drug release in vivo. In this study, three different sizes of polydopamine nanoparticles (PDA-1, PDA-2, and PDA-3) were synthesized and evaluated. PDA-2 was selected for its optimal size, encapsulation rate, and drug loading rate. The release of the drug from PDA-2@TAX was tested at different pH and NIR laser irradiation levels. The results showed that PDA-2@TAX released more readily in an acidic environment and exhibited a high photothermal conversion efficiency when exposed to an 808 nm laser. In vitro experiments on ovarian cancer cells demonstrated that PDA-2@TAX effectively inhibited cell proliferation, highlighting its potential for synergistic chemotherapy-photothermal treatment.
Collapse
Affiliation(s)
- Yang Lu
- School of Resources and Environment, Jilin Agricultural University, Changchun 130118, China
| | - Xinglong Liu
- School of Traditional Chinese Medicine, Jilin Agriculture Science and Technology College, Jilin 132101, China
| | - Ting Zhao
- School of Traditional Chinese Medicine, Jilin Agriculture Science and Technology College, Jilin 132101, China
| | - Chuanbo Ding
- School of Traditional Chinese Medicine, Jilin Agriculture Science and Technology College, Jilin 132101, China
| | - Qiteng Ding
- School of Resources and Environment, Jilin Agricultural University, Changchun 130118, China
| | - Ning Wang
- School of Resources and Environment, Jilin Agricultural University, Changchun 130118, China
| | - Shuang Ma
- School of Resources and Environment, Jilin Agricultural University, Changchun 130118, China
| | - Lina Ma
- School of Traditional Chinese Medicine, Jilin Agriculture Science and Technology College, Jilin 132101, China
| | - Wencong Liu
- School of Resources and Environment, Jilin Agricultural University, Changchun 130118, China
- School of Food and Pharmaceutical Engineering, Wuzhou University, Wuzhou 543002, China
| |
Collapse
|
2
|
Abdallah R, Atallah D, Bitar N, Chahine G, Ghanem H, Ghosn M, Kattan J, Nasr F, Makdessi J, Shamseddine A. Consensus on the management of platinum-sensitive high-grade serous epithelial ovarian cancer in Lebanon. Gynecol Oncol Rep 2023; 47:101186. [PMID: 37181681 PMCID: PMC10173395 DOI: 10.1016/j.gore.2023.101186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/18/2022] [Revised: 03/06/2023] [Accepted: 04/05/2023] [Indexed: 05/16/2023] Open
Abstract
Ovarian cancer is the most lethal gynecologic cancer. The high grade serous epithelial (HGSE) subtype is the most aggressive and it often presents at advanced stages, while screening programs have not proven beneficial. Management of the advanced stages (FIGO III and IV), which constitute the majority of diagnoses, usually consists of platinum-based chemotherapy and cytoreductive surgery (primary or interval) followed by maintenance therapy. Currently, the standard-of-care for advanced newly diagnosed HGSE ovarian cancer, as per international medical societies, starts with upfront cytoreductive surgery, followed by platinum-based chemotherapy (mostly carboplatin and paclitaxel) and/or anti-angiogenic agent bevacizumab, then maintenance therapy with a poly(ADP-ribose) polymerase (PARP) inhibitor with/without/or bevacizumab (continued). PARP inhibitor use depends on the patient's genetic signature, mainly the breast cancer gene (BRCA) mutation and the homologous recombination deficiency (HRD) status. Therefore, genetic testing is recommended at diagnosis to inform treatment and prognosis. In line with the evolving standard-of-care for ovarian cancer, a panel of experts in treating advanced ovarian cancer convened to lay down practical recommendations on the management of advanced ovarian cancer in Lebanon; since the currently applicable guidelines by the Lebanese Ministry of Public Health for cancer treatment have not been updated yet to reflect the treatment paradigm shift brought upon by the development and approval of PARP inhibitors. The current work reviews the leading clinical trials on PARP inhibitors (as maintenance for newly diagnosed advanced and platinum-sensitive relapsed ovarian cancer), presents international recommendations, and proposes treatment algorithms for optimal local practice.
Collapse
Affiliation(s)
- Reem Abdallah
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, American University of Beirut Medical Center, Beirut, Lebanon
- Corresponding author.
| | - David Atallah
- Department of Obstetrics and Gynecology, Saint Joseph University Hospital-Hôtel-Dieu de France, Beirut, Lebanon
| | - Nizar Bitar
- Department of Internal Medicine, Division of Hematology-Oncology, Sahel General Hospital, Beirut, Lebanon
| | - Georges Chahine
- Department of Hematology Oncology, Hôtel-Dieu de France – Saint Joseph University Hospital, Beirut, Lebanon
| | - Hady Ghanem
- Department of Internal Medicine, Division of Hematology/Oncology, Lebanese American University Medical Center – Rizk Hospital, Beirut, Lebanon
| | - Marwan Ghosn
- Hematology Oncology Department, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon
| | - Joseph Kattan
- Department of Hematology Oncology, Hôtel-Dieu de France – Saint Joseph University Hospital, Beirut, Lebanon
| | - Fadi Nasr
- Department of Hematology Oncology, Hôtel-Dieu de France – Saint Joseph University Hospital, Beirut, Lebanon
| | - Joseph Makdessi
- Department of Internal Medicine, Division of Hemato-Oncology, Saint George Hospital-University Medical Center, Beirut, Lebanon
| | - Ali Shamseddine
- Department of Internal Medicine, Division of Hematology-Oncology, American University of Beirut Medical Center, Beirut, Lebanon
| |
Collapse
|
3
|
Role of Bioinformatics Analysis in Early Differential Diagnosis of Ovarian Cancer. CONTRAST MEDIA & MOLECULAR IMAGING 2022; 2022:6129817. [PMID: 36185577 PMCID: PMC9507672 DOI: 10.1155/2022/6129817] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/08/2022] [Revised: 08/15/2022] [Accepted: 08/30/2022] [Indexed: 12/04/2022]
Abstract
In order to solve the problem of early differential diagnosis of ovarian cancer, this paper proposes the role of bioinformatics analysis in early differential diagnosis of ovarian cancer. This method uses bioinformatics methods to mine the existing data in the tumor database and obtain tumor-related molecules. It is an efficient method to obtain effective biomarkers, screen signal pathway molecules, and reveal the internal mechanism of tumor occurrence and development. Using this method can greatly improve the efficiency and reliability of screening diagnosis, prognosis, and treatment targets. The results showed that 5821 new lncRNA transcripts and 4611 new lncRNA genes were identified by lncScore from the assembled transcripts. 10 new lncRNA transcripts and 174 new lncRNA genes were found to be differentially expressed in ovarian cancer.
Collapse
|
4
|
Robot-assisted laparoscopic staging compared to conventional laparoscopic staging and laparotomic staging in clinical early stage ovarian carcinoma. Curr Opin Oncol 2022; 34:490-496. [PMID: 35943438 DOI: 10.1097/cco.0000000000000879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE OF REVIEW Robot-assisted laparoscopic staging (RALS) is increasingly used for staging epithelial ovarian cancer (EOC). Evidence of its safety is limited. The aim of this review is to compare the efficacy and safety of RALS in clinical early-stage EOC to conventional laparoscopy and laparotomy and to assess the level of evidence that is currently available to adopt this surgical technique. RECENT FINDINGS Only retrospective studies comparing staging by minimally invasive surgery (MIS) to laparotomy are available. Both RALS and conventional laparoscopic staging shorten length of hospital stay (LHS, mean -2.9 days) and decrease estimated blood loss (EBL, mean -79 ml less) compared to laparotomy. Complication rates and number of lymph nodes collected are similar in all surgical staging techniques. Survival outcomes after staging by MIS cannot be compared to staging by laparotomy because of the lack of evidence but RALS is probably noninferior to conventional laparoscopic staging. SUMMARY RALS probably improves perioperative outcomes in patients with clinical early stage EOC similar to conventional laparoscopic staging. Whether oncologic outcomes of RALS are comparable to open and conventional approaches is uncertain as there is only level C evidence and randomized controlled trials are urgently needed to confirm the current retrospective findings.
Collapse
|